This trial is testing a new drug for people with biliary tract cancer who can't tolerate or haven't responded to gemcitabine-based chemotherapy.
1 Primary · 2 Secondary · Reporting Duration: From therapy initiation until death, for up to 60 months
Experimental Treatment
27 Total Participants · 1 Treatment Group
Primary Treatment: XmAb20717 · No Placebo Group · Phase 2
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: